- About Us
- Research & Pipeline
- Investor Centre
- Media Centre
A prominent Australian oncology researcher says ovarian cancer patients are losing out as badly-needed funds and clinical attention is focused on more prominent – yet not as deadly – women’s diseases.
Kazia was delighted recently to have the members of our Scientific Advisory Board gather in Sydney. We spent time working through details of our clinical trials for GDC-0084, our potential brain cancer therapeutic, and Cantrixil, our drug in development for ovarian cancer. Stuart Roberts, Senior Analyst at NDF Research took the opportunity to conduct wide-ranging interviews with each of the SAB members, which provide rich insights into their work.
Kazia Therapeutics (ASX: KZA, NASDAQ: KZIA) is developing its lead therapeutic program, GDC-0084, for the deadly brain cancer, glioblastoma multiforme (GBM).
Australian biotechnology company, Novogen has announced that it will change its name to Kazia Therapeutics and that it will consolidate its share register, after the overwhelming majority of shareholders voted in favour of the proposed changes at the company's AGM held in Sydney last week.
Enter your email address to subscribe to our insights and receive notifications of new posts by email.
Required values are marked